meloxicam Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory, isoxicam derivatives 1676 71125-38-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • reumoxicam
  • miloxicam
  • meloxicam
  • metacam
  • meloxicam sodium
  • meloxicam sodium hydrate
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of meloxicam, like that of other NSAIDs, may be related to prostaglandin synthetase (cyclo-oxygenase) inhibition.
  • Molecular weight: 351.40
  • Formula: C14H13N3O4S2
  • CLOGP: 2.29
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 99.60
  • ALOGS: -3.36
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
15 mg P
15 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.71 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 97 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 18 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 13, 2000 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Spinal column injury 162.48 10.15 72 74294 1741 46609955
Rheumatoid arthritis 159.23 10.15 780 73586 239435 46372261
Surgical failure 150.22 10.15 57 74309 913 46610783
Synovial cyst 141.57 10.15 107 74259 7239 46604457
Bronchitis chronic 135.88 10.15 84 74282 4083 46607613
Accident 115.68 10.15 82 74284 5022 46606674
Arthralgia 114.58 10.15 980 73386 363623 46248073
Death 112.02 10.15 229 74137 335319 46276377
Psoriatic arthropathy 110.84 10.15 204 74162 36175 46575521
Ankylosing spondylitis 105.84 10.15 87 74279 6650 46605046
Fibromyalgia 103.04 10.15 198 74168 36265 46575431
Maternal exposure during pregnancy 95.39 10.15 23 74343 102526 46509170
Drug ineffective 92.38 10.15 1552 72814 676286 45935410
Exposure during pregnancy 90.05 10.15 30 74336 108182 46503514
Rheumatoid lung 87.01 10.15 46 74320 1654 46610042
Visual impairment 81.82 10.15 263 74103 66426 46545270
Joint swelling 81.32 10.15 497 73869 165576 46446120
Neck pain 78.95 10.15 230 74136 55076 46556620
Tenosynovitis stenosans 75.77 10.15 44 74322 1905 46609791
Pain in extremity 75.21 10.15 684 73682 257996 46353700
Musculoskeletal stiffness 74.10 10.15 331 74035 97662 46514034
Febrile neutropenia 74.03 10.15 29 74337 94598 46517098
Neutropenia 73.25 10.15 72 74294 143132 46468564
Musculoskeletal pain 73.21 10.15 262 74104 69866 46541830
Pulmonary toxicity 70.38 10.15 59 74307 4634 46607062
Linear IgA disease 70.15 10.15 37 74329 1324 46610372
Drug hypersensitivity 68.47 10.15 640 73726 243185 46368511
Tenosynovitis 67.39 10.15 71 74295 7444 46604252
Synovial fluid analysis 66.88 10.15 36 74330 1343 46610353
Breast cancer 64.68 10.15 189 74177 45329 46566367
Drug intolerance 62.08 10.15 424 73942 146625 46465071
Hypotension 61.53 10.15 179 74187 232410 46379286
Psoriasis 61.30 10.15 268 74098 78336 46533360
Neck surgery 59.38 10.15 34 74332 1433 46610263
Dry eye 57.35 10.15 140 74226 30182 46581514
Pemphigus 56.58 10.15 4 74362 45270 46566426
Toxicity to various agents 55.25 10.15 164 74202 211602 46400094
Pain 54.75 10.15 1064 73302 475884 46135812
Scleritis 52.99 10.15 41 74325 2871 46608825
Joint range of motion decreased 51.43 10.15 89 74277 15035 46596661
Bone density decreased 50.94 10.15 70 74296 9682 46602014
Antinuclear antibody positive 50.47 10.15 56 74310 6224 46605472
Peripheral swelling 47.39 10.15 421 73945 157650 46454046
Crepitations 46.70 10.15 53 74313 6039 46605657
Loss of personal independence in daily activities 46.13 10.15 197 74169 56986 46554710
Gait disturbance 45.68 10.15 391 73975 144872 46466824
Thrombocytopenia 45.06 10.15 83 74283 126498 46485198
General physical health deterioration 44.78 10.15 72 74294 115697 46495999
Bursitis 42.29 10.15 96 74270 19746 46591950
Arthritis 40.73 10.15 236 74130 77080 46534616
Product dose omission issue 40.28 10.15 428 73938 168092 46443604
Impaired work ability 39.91 10.15 72 74294 12564 46599132
Drug abuse 39.76 10.15 26 74340 63382 46548314
Viral upper respiratory tract infection 39.13 10.15 52 74314 6966 46604730
Condition aggravated 37.91 10.15 574 73792 244478 46367218
Nodule 37.23 10.15 79 74287 15526 46596170
Cardiac failure 36.64 10.15 44 74322 79904 46531792
Abortion spontaneous 36.47 10.15 12 74354 43634 46568062
Infection 35.11 10.15 346 74020 133246 46478450
Rheumatoid nodule 34.56 10.15 56 74310 8964 46602732
Bradycardia 34.26 10.15 33 74333 66265 46545431
Septic shock 33.33 10.15 26 74340 57867 46553829
Injection site pain 32.92 10.15 287 74079 106865 46504831
Cushingoid 32.76 10.15 45 74321 6221 46605475
Back pain 32.47 10.15 492 73874 209547 46402149
Therapeutic product effect decreased 32.37 10.15 234 74132 82367 46529329
Flank pain 31.59 10.15 63 74303 11850 46599846
Injection site swelling 31.04 10.15 137 74229 40190 46571506
Hyponatraemia 30.54 10.15 73 74293 101259 46510437
Pleuritic pain 30.46 10.15 44 74322 6372 46605324
Somatic delusion 29.72 10.15 16 74350 597 46611099
Pregnancy 29.72 10.15 4 74362 27133 46584563
Photophobia 29.49 10.15 69 74297 14475 46597221
Glossodynia 29.48 10.15 17 74349 44356 46567340
Malignant neoplasm progression 29.46 10.15 36 74330 64890 46546806
Intervertebral disc degeneration 29.23 10.15 65 74301 13187 46598509
Pancytopenia 29.18 10.15 57 74309 85001 46526695
Coma 29.05 10.15 30 74336 58319 46553377
Anaemia 29.01 10.15 264 74102 255515 46356181
Joint effusion 28.93 10.15 61 74305 11934 46599762
Feeling jittery 28.93 10.15 58 74308 10950 46600746
Conjunctivitis 28.93 10.15 71 74295 15353 46596343
Gastric ulcer 28.42 10.15 88 74278 21775 46589921
Off label use 28.06 10.15 431 73935 379410 46232286
Injection site erythema 27.54 10.15 208 74158 74219 46537477
Ischaemic gastritis 27.22 10.15 5 74361 0 46611696
Osteoarthritis 26.22 10.15 179 74187 61846 46549850
Pleural effusion 25.60 10.15 59 74307 82893 46528803
Intentional self-injury 25.45 10.15 4 74362 24162 46587534
Lymphomatoid papulosis 25.43 10.15 9 74357 117 46611579
Dry mouth 25.33 10.15 162 74204 54764 46556932
Cholestasis 25.05 10.15 6 74360 26887 46584809
Product use in unapproved indication 24.91 10.15 68 74298 90205 46521491
Premature delivery 24.78 10.15 3 74363 22066 46589630
Fixed eruption 24.61 10.15 16 74350 849 46610847
Acute kidney injury 23.97 10.15 250 74116 235605 46376091
Injection site reaction 23.86 10.15 144 74222 47705 46563991
Ocular hyperaemia 23.49 10.15 77 74289 19633 46592063
Gastric ulcer haemorrhage 22.55 10.15 33 74333 4835 46606861
Disease progression 22.15 10.15 73 74293 91227 46520469
Tenderness 21.99 10.15 68 74298 16813 46594883
Listless 21.48 10.15 21 74345 2014 46609682
Intentional overdose 21.01 10.15 45 74321 64899 46546797
Electrocardiogram QT prolonged 20.71 10.15 31 74335 51294 46560402
Arthropathy 20.61 10.15 216 74150 84484 46527212
Musculoskeletal discomfort 20.57 10.15 59 74307 13997 46597699
Pulmonary oedema 20.49 10.15 31 74335 51074 46560622
Pyrexia 20.24 10.15 413 73953 348389 46263307
Pulmonary arterial hypertension 20.18 10.15 8 74358 25920 46585776
Reversible airways obstruction 20.16 10.15 12 74354 544 46611152
Foetal exposure during pregnancy 20.11 10.15 12 74354 30735 46580961
Surgery 20.07 10.15 95 74271 28690 46583006
Oesophageal mucosal tear 20.07 10.15 5 74361 16 46611680
Hepatocellular injury 20.05 10.15 11 74355 29511 46582185
Poliomyelitis 19.78 10.15 6 74360 46 46611650
Drug interaction 19.53 10.15 218 74148 202876 46408820
Multiple organ dysfunction syndrome 19.20 10.15 33 74333 51677 46560019
Premature baby 19.06 10.15 3 74363 18109 46593587
HLA marker study positive 18.58 10.15 8 74358 180 46611516
Feeling abnormal 18.55 10.15 291 74075 124769 46486927
Small intestinal ulcer haemorrhage 18.46 10.15 6 74360 59 46611637
Anti-cyclic citrullinated peptide antibody positive 18.38 10.15 4 74362 19141 46592555
Tinnitus 18.34 10.15 90 74276 27583 46584113
Eyelid retraction 18.28 10.15 6 74360 61 46611635
Gastric mucosal hypertrophy 18.20 10.15 6 74360 62 46611634
Hypoaesthesia 18.16 10.15 278 74088 118591 46493105
Ulcer 18.15 10.15 65 74301 17327 46594369
Nodular rash 18.14 10.15 8 74358 191 46611505
Eye irritation 18.12 10.15 63 74303 16551 46595145
Respiratory failure 17.78 10.15 84 74282 94732 46516964
Pericarditis 17.63 10.15 8 74358 23919 46587777
Allergy to chemicals 17.53 10.15 13 74353 854 46610842
Cataract 17.40 10.15 128 74238 45287 46566409
Malaise 17.11 10.15 667 73699 330565 46281131
Head discomfort 16.68 10.15 45 74321 10306 46601390
Therapy cessation 16.51 10.15 85 74281 26544 46585152
Breast cancer female 16.37 10.15 32 74334 5931 46605765
Parotid gland enlargement 16.27 10.15 12 74354 782 46610914
Bone marrow failure 16.24 10.15 14 74352 29655 46582041
Pharyngeal paraesthesia 16.10 10.15 14 74352 1156 46610540
Tubulointerstitial nephritis 16.06 10.15 56 74310 14732 46596964
Rash pruritic 16.03 10.15 123 74243 44092 46567604
Epilepsy 15.90 10.15 9 74357 23729 46587967
Stress fracture 15.76 10.15 35 74331 7092 46604604
Platelet count decreased 15.76 10.15 94 74272 99930 46511766
Hepatic cirrhosis 15.70 10.15 3 74363 15729 46595967
Agranulocytosis 15.46 10.15 8 74358 22177 46589519
Anhidrosis 15.38 10.15 6 74360 104 46611592
Dyspnoea 15.23 10.15 669 73697 514879 46096817
Respiratory distress 15.22 10.15 17 74349 31899 46579797
Pre-existing condition improved 15.22 10.15 33 74333 6579 46605117
Eye pain 15.17 10.15 86 74280 27854 46583842
Hypoxia 15.09 10.15 38 74328 51800 46559896
Device expulsion 15.07 10.15 13 74353 27529 46584167
Nephrolithiasis 14.94 10.15 97 74269 32954 46578742
Vital capacity decreased 14.92 10.15 10 74356 559 46611137
Eosinophilia 14.84 10.15 6 74360 19211 46592485
International normalised ratio increased 14.74 10.15 33 74333 46850 46564846
Sepsis 14.70 10.15 142 74224 135872 46475824
Finger deformity 14.53 10.15 28 74338 5134 46606562
Rhabdomyolysis 14.44 10.15 28 74338 41881 46569815
Small intestine ulcer 14.40 10.15 8 74358 318 46611378
Neutrophil count decreased 14.12 10.15 30 74336 43396 46568300
Cardiac failure congestive 14.04 10.15 87 74279 91663 46520033
Injection site bruising 13.98 10.15 101 74265 35535 46576161
Injection site warmth 13.97 10.15 51 74315 13721 46597975
Tachycardia 13.97 10.15 97 74269 99525 46512171
Sputum culture positive 13.93 10.15 12 74354 978 46610718
Purpura senile 13.92 10.15 10 74356 625 46611071
Acute myeloid leukaemia 13.78 10.15 4 74362 15774 46595922
Therapy non-responder 13.74 10.15 28 74338 41124 46570572
Leukopenia 13.74 10.15 59 74307 68284 46543412
Injection site vesicles 13.72 10.15 19 74347 2646 46609050
Muscular weakness 13.72 10.15 214 74152 91630 46520066
Asterixis 13.55 10.15 13 74353 1218 46610478
Mucosal inflammation 13.46 10.15 26 74340 38950 46572746
Hypermobility syndrome 13.32 10.15 10 74356 669 46611027
Jaundice neonatal 13.25 10.15 11 74355 852 46610844
Neoplasm malignant 13.20 10.15 73 74293 23426 46588270
Joint stiffness 13.14 10.15 81 74285 27027 46584669
Atelectasis 13.09 10.15 62 74304 18728 46592968
Carpal tunnel syndrome 13.06 10.15 55 74311 15804 46595892
Posterior reversible encephalopathy syndrome 12.93 10.15 4 74362 15137 46596559
Pneumonia aspiration 12.84 10.15 19 74347 31586 46580110
Seizure 12.66 10.15 130 74236 122924 46488772
Sinusitis 12.65 10.15 283 74083 129485 46482211
Resorption bone increased 12.59 10.15 12 74354 1115 46610581
Cerebral haemorrhage 12.58 10.15 16 74350 28355 46583341
Lumbar spinal stenosis 12.57 10.15 24 74342 4371 46607325
Clostridium difficile colitis 12.47 10.15 7 74359 18546 46593150
General symptom 12.44 10.15 17 74349 2338 46609358
Lip swelling 12.39 10.15 76 74290 25319 46586377
Loss of consciousness 12.16 10.15 241 74125 107997 46503699
Overdose 12.09 10.15 104 74262 101875 46509821
Suicide attempt 12.01 10.15 46 74320 54990 46556706
Focal segmental glomerulosclerosis 11.99 10.15 13 74353 1408 46610288
Hyperkalaemia 11.98 10.15 41 74325 50668 46561028
Cytomegalovirus infection 11.98 10.15 7 74359 18137 46593559
Kyphoscoliosis 11.94 10.15 8 74358 447 46611249
Blood creatinine increased 11.93 10.15 72 74294 76331 46535365
Depression 11.91 10.15 355 74011 169749 46441947
Intervertebral disc protrusion 11.87 10.15 64 74302 20341 46591355
Swelling face 11.83 10.15 133 74233 52926 46558770
Mobility decreased 11.80 10.15 148 74218 60446 46551250
Hepatic failure 11.80 10.15 22 74344 33394 46578302
Ejection fraction decreased 11.73 10.15 7 74359 17930 46593766
Enthesopathy 11.48 10.15 24 74342 4666 46607030
Red blood cell sedimentation rate increased 11.48 10.15 69 74297 22820 46588876
Interstitial lung disease 11.48 10.15 134 74232 53815 46557881
Tarsal tunnel syndrome 11.44 10.15 9 74357 646 46611050
Hepatotoxicity 11.20 10.15 14 74352 24995 46586701
Urticaria 11.14 10.15 127 74239 117765 46493931
Antinuclear antibody 11.13 10.15 8 74358 501 46611195
Encephalopathy 11.09 10.15 23 74343 33566 46578130
Neutropenic sepsis 11.00 10.15 3 74363 12321 46599375
Small intestinal stenosis 10.97 10.15 8 74358 512 46611184
Vertigo 10.95 10.15 129 74237 51919 46559777
Spinal operation 10.92 10.15 26 74340 5514 46606182
Manipulation 10.90 10.15 4 74362 58 46611638
Neoplasm progression 10.88 10.15 16 74350 26667 46585029
Hypoglycaemia 10.87 10.15 47 74319 54302 46557394
Wrong drug 10.84 10.15 5 74361 133 46611563
Dysphoria 10.68 10.15 23 74343 4566 46607130
Urine odour abnormal 10.56 10.15 24 74342 4938 46606758
Foreign body 10.54 10.15 14 74352 1874 46609822
Plantar fasciitis 10.54 10.15 17 74349 2711 46608985
Sacroiliitis 10.48 10.15 15 74351 2154 46609542
Symptom recurrence 10.48 10.15 7 74359 389 46611307
Bronchial secretion retention 10.46 10.15 10 74356 933 46610763
Generalised tonic-clonic seizure 10.35 10.15 17 74349 27105 46584591
Lacrimation decreased 10.35 10.15 7 74359 397 46611299
Myofascial pain syndrome 10.35 10.15 14 74352 1907 46609789
Spinal cord herniation 10.25 10.15 3 74363 20 46611676
Wrong schedule 10.17 10.15 5 74361 154 46611542

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 123.66 11.91 162 24097 42344 29885875
Psoriatic arthropathy 90.93 11.91 86 24173 15675 29912544
Arthralgia 76.77 11.91 263 23996 135528 29792691
Gastric haemorrhage 69.11 11.91 59 24200 9408 29918811
Joint swelling 56.08 11.91 120 24139 46826 29881393
Ankylosing spondylitis 49.87 11.91 36 24223 4498 29923721
Lipoma 46.11 11.91 23 24236 1460 29926759
Intestinal diaphragm disease 45.03 11.91 14 24245 245 29927974
Duodenal ulcer 44.16 11.91 47 24212 9854 29918365
Pain 43.29 11.91 263 23996 172378 29755841
Seronegative arthritis 35.71 11.91 16 24243 797 29927422
Neutropenia 34.46 11.91 32 24227 128508 29799711
Musculoskeletal stiffness 34.28 11.91 84 24175 35797 29892422
Gastrointestinal haemorrhage 34.17 11.91 146 24113 83300 29844919
Xyphoid retraction 32.65 11.91 10 24249 166 29928053
Arthropathy 31.98 11.91 59 24200 20668 29907551
Surgery 31.97 11.91 43 24216 11508 29916711
Osteoarthritis 31.87 11.91 55 24204 18294 29909925
Pain in extremity 30.22 11.91 172 24087 110049 29818170
Arthritis 29.84 11.91 63 24196 24338 29903881
Drug ineffective 29.60 11.91 412 23847 339975 29588244
Back pain 28.71 11.91 161 24098 102435 29825784
Gastric ulcer 28.48 11.91 47 24212 15074 29913145
Febrile neutropenia 26.93 11.91 28 24231 106665 29821554
Thrombocytopenia 26.37 11.91 44 24215 137000 29791219
Oesophageal infection 26.01 11.91 9 24250 223 29927996
Product dose omission issue 25.77 11.91 144 24115 91487 29836732
Exostosis 24.13 11.91 21 24238 3434 29924785
Epstein Barr virus positive mucocutaneous ulcer 21.59 11.91 8 24251 243 29927976
Inflammatory marker increased 21.51 11.91 19 24240 3169 29925050
Oropharyngeal pain 21.40 11.91 61 24198 28435 29899784
Arthrofibrosis 21.31 11.91 6 24253 73 29928146
Finger deformity 21.25 11.91 12 24247 980 29927239
Injection site erythema 20.86 11.91 39 24220 13795 29914424
Drug hypersensitivity 20.14 11.91 109 24150 68410 29859809
Off label use 19.61 11.91 120 24139 249170 29679049
General physical health deterioration 19.30 11.91 32 24227 99912 29828307
Sinusitis 19.13 11.91 65 24194 33280 29894939
Acute generalised exanthematous pustulosis 18.89 11.91 24 24235 6074 29922145
Foot deformity 18.39 11.91 18 24241 3419 29924800
Juvenile idiopathic arthritis 18.08 11.91 11 24248 1032 29927187
Foot fracture 17.19 11.91 19 24240 4153 29924066
Duodenal ulcer haemorrhage 17.09 11.91 20 24239 4652 29923567
Fixed eruption 16.80 11.91 11 24248 1173 29927046
Rheumatoid arthritis 16.77 11.91 72 24187 41125 29887094
Death 16.42 11.91 198 24061 357085 29571134
Intervertebral disc protrusion 16.37 11.91 28 24231 9243 29918976
Cellulitis gangrenous 16.23 11.91 6 24253 181 29928038
Tendon disorder 16.13 11.91 14 24245 2282 29925937
Uveitis 16.09 11.91 21 24238 5456 29922763
Therapeutic product effect incomplete 16.05 11.91 62 24197 33772 29894447
Skin ulcer 15.79 11.91 42 24217 18807 29909412
Multiple organ dysfunction syndrome 15.63 11.91 17 24242 63470 29864749
Sleep apnoea syndrome 15.60 11.91 39 24220 16818 29911401
Hypokalaemia 15.29 11.91 11 24248 50181 29878038
Musculoskeletal discomfort 15.26 11.91 22 24237 6278 29921941
Electrocardiogram QRS complex prolonged 15.13 11.91 18 24241 4259 29923960
Leukopenia 15.01 11.91 14 24245 56145 29872074
Product physical issue 14.75 11.91 13 24246 2161 29926058
Headache 14.70 11.91 218 24041 182088 29746131
Knee arthroplasty 14.13 11.91 20 24239 5610 29922609
Cartilage injury 14.10 11.91 7 24252 440 29927779
Injection site bruising 14.07 11.91 23 24236 7315 29920904
Eyelid margin crusting 13.77 11.91 5 24254 143 29928076
Streptococcal infection 13.75 11.91 18 24241 4690 29923529
Joint space narrowing 13.69 11.91 4 24255 56 29928163
Hip arthroplasty 13.66 11.91 16 24243 3724 29924495
Ascites 13.63 11.91 6 24253 35915 29892304
Joint stiffness 13.63 11.91 26 24233 9335 29918884
Iritis 13.55 11.91 10 24249 1292 29926927
Water intoxication 13.33 11.91 7 24252 495 29927724
Duodenal ulcer perforation 13.28 11.91 11 24248 1681 29926538
Injection site haemorrhage 12.93 11.91 23 24236 7832 29920387
Peptic ulcer perforation 12.80 11.91 5 24254 176 29928043
Therapeutic product effect decreased 12.76 11.91 52 24207 29024 29899195
Hernia 12.49 11.91 24 24235 8662 29919557
Prostatic specific antigen increased 12.42 11.91 29 24230 11975 29916244
Gastrointestinal injury 12.34 11.91 6 24253 360 29927859
Ankle fracture 12.32 11.91 15 24244 3636 29924583
Skin exfoliation 12.27 11.91 44 24215 23128 29905091
Inappropriate schedule of product administration 12.21 11.91 64 24195 39664 29888555
Neck pain 12.16 11.91 41 24218 20903 29907316
Hypotension 12.14 11.91 104 24155 200461 29727758
Lumbar radiculopathy 12.03 11.91 8 24251 875 29927344
Hypoaesthesia 11.92 11.91 80 24179 54150 29874069

Pharmacologic Action:

SourceCodeDescription
ATC M01AC06 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Oxicams
ATC M01AC56 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Oxicams
ATC N01BB59 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
FDA CS M0001335 Anti-Inflammatory Agents, Non-Steroidal
FDA MoA N0000000160 Cyclooxygenase Inhibitors
FDA EPC N0000175722 Nonsteroidal Anti-inflammatory Drug
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D052246 Cyclooxygenase 2 Inhibitors
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drugs
CHEBI has role CHEBI:35842 antirheumatic agent
CHEBI has role CHEBI:50629 cyclooxygenase-2 inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Rheumatoid arthritis indication 69896004 DOID:7148
Osteoarthritis indication 396275006
Juvenile rheumatoid arthritis indication 410795001
Ankylosing spondylitis off-label use 9631008 DOID:7147
Gastritis contraindication 4556007 DOID:4029
Alcoholism contraindication 7200002
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Gastrointestinal perforation contraindication 51875005
Hyperlipidemia contraindication 55822004 DOID:1168
Blood coagulation disorder contraindication 64779008 DOID:1247
Aortocoronary artery bypass graft contraindication 67166004
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Coronary artery bypass graft contraindication 232717009
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Smokes tobacco daily contraindication 449868002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.65 acidic
pKa2 5.42 acidic
pKa3 4.32 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
30MG/ML (30MG/ML) ANJESO BAUDAX N210583 Feb. 20, 2020 RX SOLUTION INTRAVENOUS Feb. 20, 2023 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 6.80 CHEMBL CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 5.85 CHEMBL

External reference:

IDSource
4021203 VUID
N0000148649 NUI
D00969 KEGG_DRUG
4021203 VANDF
C0083381 UMLSCUI
CHEBI:6741 CHEBI
MXM PDB_CHEM_ID
CHEMBL599 ChEMBL_ID
CHEMBL1256873 ChEMBL_ID
D000077239 MESH_DESCRIPTOR_UI
DB00814 DRUGBANK_ID
7220 IUPHAR_LIGAND_ID
5615 INN_ID
VG2QF83CGL UNII
54677470 PUBCHEM_CID
1086708 RXNORM
84146 MMSL
8839 MMSL
d04532 MMSL
006272 NDDF
125694008 SNOMEDCT_US
387055000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 0440-5841 TABLET 7.50 mg ORAL ANDA 28 sections
Mobic HUMAN PRESCRIPTION DRUG LABEL 1 0597-0029 TABLET 7.50 mg ORAL NDA 28 sections
Mobic HUMAN PRESCRIPTION DRUG LABEL 1 0597-0030 TABLET 15 mg ORAL NDA 28 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 0615-8040 TABLET 7.50 mg ORAL ANDA 26 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 0615-8124 TABLET 15 mg ORAL ANDA 26 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-052 TABLET 15 mg ORAL ANDA 31 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-090 TABLET 7.50 mg ORAL ANDA 31 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-251 TABLET 15 mg ORAL ANDA 27 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-252 TABLET 7.50 mg ORAL ANDA 27 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-555 TABLET 15 mg ORAL ANDA 25 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-631 TABLET 7.50 mg ORAL ANDA 25 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 10544-925 TABLET 15 mg ORAL ANDA 26 sections
Meloxicam Human Prescription Drug Label 1 16571-776 TABLET 7.50 mg ORAL ANDA 28 sections
Meloxicam Human Prescription Drug Label 1 16571-777 TABLET 15 mg ORAL ANDA 28 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 16590-434 TABLET 7.50 mg ORAL ANDA 18 sections
MELOXICAM HUMAN PRESCRIPTION DRUG LABEL 1 16590-469 TABLET 15 mg ORAL ANDA 18 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 21695-076 TABLET 7.50 mg None ANDA 26 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 21695-077 TABLET 15 mg ORAL ANDA 26 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 29300-124 TABLET 7.50 mg ORAL ANDA 27 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 29300-125 TABLET 15 mg ORAL ANDA 27 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 33261-070 TABLET 7.50 mg ORAL ANDA 25 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 33261-071 TABLET 15 mg ORAL ANDA 25 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 35356-808 TABLET 7.50 mg ORAL ANDA 25 sections
Vivlodex HUMAN PRESCRIPTION DRUG LABEL 1 42211-205 CAPSULE 5 mg ORAL NDA 28 sections
Vivlodex HUMAN PRESCRIPTION DRUG LABEL 1 42211-206 CAPSULE 10 mg ORAL NDA 28 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 42549-519 TABLET 15 mg ORAL ANDA 27 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 42549-604 TABLET 7.50 mg ORAL ANDA 27 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 42708-007 TABLET 15 mg ORAL ANDA 27 sections
meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 42708-093 TABLET 7.50 mg ORAL ANDA 27 sections
Meloxicam HUMAN PRESCRIPTION DRUG LABEL 1 43063-395 TABLET 7.50 mg ORAL ANDA 31 sections